8-K: Vaxart Shareholders Reject Reverse Stock Split and Executive Pay Amidst Annual Meeting Delays

Vaxart, Inc. announced the preliminary results of its reconvened 2025 Annual Meeting of Stockholders, revealing that while directors were elected and auditors ratified, shareholders rejected key proposals for a reverse stock split and executive compensation.

Summary

• Vaxart, Inc. held its reconvened 2025 Annual Meeting of Stockholders on June 13, 2025, after previous adjournments on May 21, 2025, and June 2, 2025.
• A quorum was established with proxies representing approximately 68.4% of outstanding shares.
• Stockholders elected all six director nominees to serve until the 2026 annual meeting.
• Stockholders ratified WithumSmith+Brown, PC as the company's independent registered public accounting firm for the year ending December 31, 2025.
• Stockholders did not approve an amendment to the company's Restated Certificate of Incorporation to effect a reverse stock split, with 91,897,715 votes against versus 63,604,351 votes for.
• Stockholders did not approve, on a non-binding, advisory basis, the 2024 compensation of the company's named executive officers, with 71,451,726 votes against versus 34,400,261 votes for.
• The company has an 'at the market facility' (ATM Facility) in place but has not sold any amounts under it as of June 13, 2025.
• A special meeting of stockholders previously scheduled for June 30, 2025, has been cancelled.

Sentiment

Score: 3

Explanation: The sentiment is largely negative due to the significant shareholder rejection of two key management-backed proposals (reverse stock split and executive compensation), indicating strong dissent and potential challenges for the company's strategic and financial flexibility. The repeated adjournments of the annual meeting also suggest underlying issues.

Positives

• The six director nominees were successfully elected by stockholders, ensuring continuity in board leadership.
• WithumSmith+Brown, PC was ratified as the independent registered public accounting firm for 2025, maintaining financial oversight.

Negatives

• Stockholders rejected the proposed reverse stock split (ratio of 1-for-5 to 1-for-50), which was likely intended to manage share price or meet listing requirements.
• Stockholders rejected, on a non-binding advisory basis, the 2024 compensation for named executive officers, indicating significant shareholder dissatisfaction with executive pay.

Risks

• The company faces continuing operating losses.
• There is uncertainty regarding market acceptance of the company's products.
• The company relies on third-party manufacturers.
• The company has an accumulated deficit.
• There are future capital needs and uncertainty of capital funding.
• The company depends on a limited product line and distribution channels.
• The company faces competition in its industry.
• The company has limited marketing and manufacturing experience.
• There is no assurance that meetings for potential collaborations will result in any actual collaboration.
• Forward-looking statements may turn out to be inaccurate due to various factors.

Future Outlook

Vaxart is evaluating its options regarding the rejected reverse stock split. The company plans to attend a conference during the week of June 16, 2025, to explore potential collaborations, though there is no guarantee of success. The company also noted it has an 'at the market facility' (ATM Facility) in place but has not utilized it as of June 13, 2025.

Management Comments

• The Company is evaluating its options as to next steps regarding the rejected reverse stock split.
• The Company currently has an at the market facility (the ATM Facility) in place and, as of the morning of June 13, 2025, the Company has not sold any amounts under the ATM Facility.
• The Company also is attending a conference during the week of June 16, 2025 at which it plans to meet with various companies for potential collaborations. There is no assurance that such meetings will results in any collaboration.

Industry Context

Vaxart operates as a clinical-stage biotechnology company focused on developing oral recombinant pill vaccines, a niche within the broader pharmaceutical and vaccine industry. Their proprietary delivery platform aims to offer advantages like no refrigeration and no needle-stick injury risk. The shareholder dissent reflected in the rejection of the reverse stock split and executive compensation is not uncommon for clinical-stage biotech companies, which often face long development timelines, significant capital requirements, and intense scrutiny from investors regarding financial management and strategic direction.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Directly impacted by the rejection of the reverse stock split, which could affect share price and liquidity. The rejection of executive compensation reflects shareholder dissatisfaction with management pay and governance.
• **Management/Executives**: Their 2024 compensation was rejected on an advisory basis, indicating a lack of shareholder confidence in their pay structure. The CEO, Steven Lo, is noted as signing the report.
• **Employees**: Indirectly impacted by the company's strategic direction and financial health, which could be influenced by the outcomes of the meeting and future capital needs.
• **Auditors**: WithumSmith+Brown, PC was ratified, ensuring continuity in the company's financial auditing and oversight.

Next Steps

• Vaxart is evaluating its options regarding the rejected reverse stock split.
• The company plans to meet with various companies for potential collaborations during the week of June 16, 2025.
• The final results of the Annual Meeting are subject to verification by the inspector of elections and will be reported on a future Current Report on Form 8-K.

Key Dates

Recommendation

Keywords

Vaxart, VXRT, SEC filing, 8-K, Annual Meeting, Stockholders, Reverse Stock Split, Executive Compensation, Corporate Governance, Biotechnology, Vaccine Development, Oral Vaccines, Clinical-stage, Nasdaq